Log In
BCIQ
Print this Print this
 

biosimilar infliximab (GP 1111, PF-06438179)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionBiosimilar of infliximab, a chimeric mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/12/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today